Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it will present data on investigational compounds in the AML Franchise pipeline of the Daiichi Sankyo Cancer Enterprise at the 60th Annual Meeting of the American Society of Hematology (ASH) from December 1-4 in San Diego.
Three patients with chronic paraplegia were able to walk over ground thanks to precise electrical stimulation of their spinal cords via a wireless implant. In a double study published in Nature and Nature Neuroscience, Swiss scientists Grégoire Courtine (EPFL and CHUV/Unil) and Jocelyne Bloch (CHUV/Unil) show that, after a few months of training, the patients were able to control previously paralyzed leg muscles even in the absence of electrical stimulation.
Bain Capital, LP and Pfizer Inc. today announced the creation of Cerevel Therapeutics, LLC (“Cerevel”), a new biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). Pfizer is contributing a portfolio of pre-commercial neuroscience assets to Cerevel, which include three clinical- stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction.
Two-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1 or 2 mutation, results from the phase 3 SOLO-1 trial show. (1)
Including exercise or sport as part of cancer care can significantly improve symptom management, quality of life and fitness during and after treatment, French researchers have concluded in two presentations to be reported at the ESMO 2018 Congress in Munich. Even among patients at highest risk of poor quality of life, exercise can make a difference.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will be presenting results from 13 abstracts across the company’s rheumatology portfolio and pipeline products during the 2018 American College of Rheumatology (ACR) / Association for Rheumatology Health Professionals (ARHP) Annual Meeting taking place in Chicago, IL, from 19–24 October.
For some patients with difficult-to-treat leukemia and lymphoma, the investigational oral medicine duvelisib may significantly improve disease outcomes, according to phase III trial data published in the journal Blood.
Being overweight or obese may put adults with diabetes at greater risk of dying from cancer than their diabetes-free counterparts, particularly for obesity-related cancers such as those arising from the bowel, kidney, and pancreas in men and women, and from the breast and endometrium (lining of the uterus) in women, according to a large observational study being presented at this year’s European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin, Germany (1–5 October).
A clinical trial testing infusions of combination antibodies in people living with HIV has begun at the National Institutes of Health. The early phase clinical trial will evaluate whether periodic infusions of two highly potent, HIV-specific, broadly neutralizing antibodies (bNAbs)—3BNC117 and 10-1074—are safe in people living with HIV. The study also will gather preliminary data on how effectively the bNAb infusions, delivered together every two to four weeks, suppress HIV following discontinuation of antiretroviral therapy (ART).